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PRACTICE GUIDELINES
 Recent population studies suggest that gastroesophageal refl ux 
disease (GERD) is increasing in prevalence, both in the United 
States and worldwide ( 1,2 ). Th e diagnosis of GERD is associated 
with a 10–15% risk of Barrett’s esophagus (BE), a change of the 
normal squamous epithelium of the distal esophagus to a co-
lumnar-lined intestinal metaplasia (IM). Risk factors associated 
with the development of BE include long-standing GERD, male 
gender, central obesity ( 3 ), and age over 50 years ( 4,5 ). Th e goal 
of a screening and surveillance program for BE is to identify in-
dividuals at risk for progression to esophageal adenocarcinoma 
(EAC), a malignancy that has been increasing in incidence since 
the 1970s ( 6,7 ).
 Th e purpose of this guideline is to review the defi nition and 
epidemiology of BE, available screening modalities for BE detec-
tion, rationale and methods for surveillance, and available treat-
ment modalities including medical, endoscopic, and surgical 
techniques. In order to evaluate the level of evidence and strength 
of recommendations, we used the GRADE (Grading of Recom-
mendations Assessment, Development and Evaluation) system 
( 8 ). Th e level of evidence ranged from “high” (implying that fur-
ther research was unlikely to change the authors’ confi dence in the 
estimate of the eff ect) to “moderate” (further research would be 
likely to have an impact on the confi dence in the estimate of eff ect) 
to “low” (further research would be expected to have an important 
impact on the confi dence in the estimate of the eff ect and would be 
likely to change the estimate) or “very low” (any estimate of eff ect 
is very uncertain). Th e strength of a recommendation was graded 
as “strong” when the desirable eff ects of an intervention clearly 
outweighed the undesirable eff ects and as “conditional” when 
there was uncertainty about the tradeoff s. We used meta-analyses 
or systematic reviews when available, followed by clinical trials and 
cohort and case–control studies. In order to determine the level 
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of evidence, we entered data from the papers of highest evidence 
into the GRADE program (accessible at  www.gradepro.org ). For 
each recommendation, a GRADE table was constructed, and the 
evidence rated. Recommendation statements were structured in 
the “PICO” format (patient population involved, intervention or 
Indicator assessed, comparison group, and patient-relevant out-
come achieved) when possible. Th e aggregate recommendation 
statements are in  Table 1 .
 As part of this guideline preparation, a literature search was 
conducted using Ovid MEDLINE from 1946 to present, EMBASE 
1988 to present, and SCOPUS from 1980 to present using major 
search terms and subheadings including “Barrett esophagus,” 
“Barrett oesophagus,” “epithelium,” “goblet cells,” “metaplasia,” 
“dysplasia,” “precancerous conditions,” “adenocarcinoma,” “radio-
frequency,” “catheter ablation,” “early detection of cancer,” “mass 
screening,” and/or “esophagoscopy,” Th e full literature search strat-
egy is demonstrated in  Supplementary Appendix 1 online.
 DIAGNOSIS OF BE
 Recommendations 
 1 .  BE should be diagnosed when there is extension of salmon-
colored mucosa into the tubular esophagus extending ≥1 cm 
proximal to the gastroesophageal junction (GEJ) with biopsy 
confi rmation of IM (strong recommendation, low level of 
evidence). 
 2 .  Endoscopic biopsy should not be performed in the presence 
of a normal Z line or a Z line with <1 cm of variability (strong 
recommendation, low level of evidence). 
 3 .  In the presence of BE, the endoscopist should describe the 
extent of metaplastic change including circumferential and 
maximal segment length using the Prague classifi cation 
(conditional recommendation, low level of evidence). 
 4 .  Th e location of the diaphragmatic hiatus, GEJ, and squa-
mocolumnar junction should be reported in the endoscopy 
report (conditional recommendation, low level of evidence). 
 5 .  In patients with suspected BE, at least 8 random biopsies 
should be obtained to maximize the yield of IM on histology. 
In patients with short (1–2 cm) segments of suspected BE in 
whom 8 biopsies may be unobtainable, at least 4 biopsies per 
cm of circumferential BE, and one biopsy per cm in tongues 
of BE, should be obtained (conditional recommendation, low 
level of evidence). 
 6 .  In patients with suspected BE and lack of IM on histology, a 
repeat endoscopy should be considered in 1–2 years of time 
to rule out BE (conditional recommendation, very low level 
of evidence). 
 Summary of evidence
 Establishing a diagnosis of BE .  BE has been traditionally defi ned 
as the presence of at least 1 cm of metaplastic columnar epithelium 
that replaces the stratifi ed squamous epithelium normally lining 
the distal esophagus. Th e reason why such segments <1 cm have 
been classifi ed as “specialized IM of the esophagogastric junction” 
(SIM-EGJ) and not BE is because of high interobserver variability, 
as well as the low risk for EAC. Patients with SIM-EGJ have not 
demonstrated an increase in the development of dysplasia or EAC 
in large cohort studies aft er long-term follow-up, in contrast with 
patients with segments of IM >1 cm ( 9 ).
 Th e defi nition of BE has varied depending upon the require-
ment for the presence of IM on endoscopic biopsy. Th e presence of 
IM has traditionally been a requirement for the diagnosis of BE in 
the United States. On the other hand, guidelines from the United 
Kingdom have considered BE to be present if there was visual evi-
dence of columnar-lined epithelium (CLE) on endoscopic exami-
nation and biopsies demonstrated columnar metaplasia, regardless 
of the presence of IM ( 10 ). Th e debate regarding the requirement 
of IM on biopsy from CLE segments has derived from the appar-
ently diff erential risk of developing EAC in CLE containing IM 
compared with non-IM CLE. Large population-based cohort stud-
ies have demonstrated a substantially lower EAC risk in subjects 
with columnar metaplasia without IM compared with those with 
IM ( 11 ). However, not all studies have corroborated this fi nding 
( 12 ). Although DNA content abnormalities appear to be compara-
ble in both metaplastic epithelium without goblet cells compared 
with metaplastic epithelium with goblet cells, other studies sug-
gest that cancer most commonly occurs in columnar metaplasia 
with goblet cells compared with columnar metaplasia without gob-
let cells ( 11,13,14 ). Even if the rate of EAC is markedly higher in 
CLE containing IM, another complicating factor is sampling error 
leading to misclassifi cation of IM-containing CLE as non-IM CLE. 
Th e yield for IM correlates directly with the number of endoscopic 
biopsies obtained. In a large retrospective study, the yield for IM 
was 35% if 4 biopsies were obtained, and up to 68% aft er 8 biopsies 
were performed ( 15 ). Despite the incompletely elucidated risk of 
EAC in non-IM CLE, and acknowledging the potential for sam-
pling error, we continue to suggest that only CLE containing IM be 
defi ned as BE, given the apparent diff erential cancer risk between 
CLE containing IM and CLE without IM. Until and unless fur-
ther work substantiates a markedly elevated risk of EAC in non-IM 
CLE patients, it is unwise to give these patients a disease diagnosis 
that has a documented negative impact on insurance status and 
quality of life ( 16,17 ).
 IM of cardia is very common, being described in up to 20% of 
asymptomatic subjects presenting for routine open access endo-
scopic examinations ( 18 ). Studies have suggested that IM of the 
cardia is not more common in BE patients compared with con-
trols ( 19 ), and that the natural history of IM at the EGJ is asso-
ciated with  Helicobacter pylori infection and not associated with 
EAC ( 20 ). Based on this information, biopsy of a normal or slightly 
irregular EGJ is not recommended.
 Th e location of the EGJ has been defi ned as the anatomic region 
where the distal extent of the tubular esophagus is in contact with 
the proximal extent of the gastric folds. Th e location of the proxi-
mal extent of the gastric folds can be aff ected by respiration, air 
insuffl  ation during endoscopy, and esophageal and gastric motil-
ity. For this reason, some Japanese endoscopists have chosen to 
defi ne the location of the EGJ based on the distal limit of the lower 
esophageal palisade vessels ( 21 ). Using this methodology, how-
ever, the lower esophageal palisade vessel has been described to 
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 Table 1 .  Recommendation statements 
 Diagnosis of BE 
  1. BE should be diagnosed when there is extension of salmon-colored mucosa into the tubular esophagus extending ≥1 cm proximal to the gastroesopha-
geal junction with biopsy confi rmation of IM (strong recommendation, low level of evidence). 
  2. Endoscopic biopsy should not be performed in the presence of a normal Z line or a Z line with <1 cm of variability (strong recommendation, low level of 
evidence). 
  3. In the presence of BE, the endoscopist should describe the extent of metaplastic change including circumferential and maximal segment length using 
the Prague classifi cation (conditional recommendation, low level of evidence). 
  4. The location of the diaphragmatic hiatus, gastroesophageal junction, and squamocolumnar junction should be reported in the endoscopy report (condi-
tional recommendation, low level of evidence). 
  5. In patients with suspected BE, at least 8 random biopsies should be obtained to maximize the yield of IM on histology. In patients with short (1–2 cm) 
segments of suspected BE in whom 8 biopsies are unattainable, at least 4 biopsies per cm of circumferential BE, and one biopsy per cm in tongues of BE, 
should be taken (conditional recommendation, low level of evidence). 
  6. In patients with suspected BE and lack of IM on histology, a repeat endoscopy should be considered in 1–2 years of time to rule out BE (conditional 
recommendation, very low level of evidence). 
 Screening for BE 
  7. Screening for BE may be considered in men with chronic (>5 years) and/or frequent (weekly or more) symptoms of gastroesophageal refl ux (heartburn or 
acid regurgitation) and two or more risk factors for BE or EAC. These risk factors include: age >50 years, Caucasian race, presence of central obesity (waist 
circumference >102 cm or waist–hip ratio (WHR) >0.9), current or past history of smoking, and a confi rmed family history of BE or EAC (in a fi rst-degree 
relative) (strong recommendation, moderate level of evidence). 
  8. Given the substantially lower risk of EAC in females with chronic GER symptoms (when compared with males), screening for BE in females is not 
recommended. However, screening could be considered in individual cases as determined by the presence of multiple risk factors for BE or EAC (age >50 
years, Caucasian race, chronic and/or frequent GERD, central obesity: waist circumference >88 cm, WHR >0.8, current or past history of smoking, and a 
confi rmed family history of BE or EAC (in a fi rst-degree relative)) (strong recommendation, low level of evidence). 
  9. Screening of the general population is not recommended (conditional recommendation, low level of evidence). 
  10. Before screening is performed, the overall life expectancy of the patient should be considered, and subsequent implications, such as the need for peri-
odic endoscopic surveillance and therapy, if BE with dysplasia is diagnosed, should be discussed with the patient (strong recommendation, very low level of 
evidence). 
  11. Unsedated transnasal endoscopy (uTNE) can be considered as an alternative to conventional upper endoscopy for BE screening (strong recommenda-
tion, low level of evidence). 
  12. If initial endoscopic evaluation is negative for BE, repeating endoscopic evaluation for the presence of BE is not recommended. If endoscopy reveals 
esophagitis (Los Angeles Classifi cation B, C, D), repeat endoscopic assessment after PPI therapy for 8–12 weeks is recommended to ensure healing of 
esophagitis and exclude the presence of underlying BE (conditional recommendation, low level of evidence). 
 Surveillance of BE 
  13. Patients should only undergo surveillance after adequate counseling regarding risks and benefi ts of surveillance (strong recommendation, very low level 
of evidence). 
  14. Surveillance should be performed with high-defi nition/high-resolution white light endoscopy (strong recommendation, low level of evidence). 
  15. Routine use of advanced imaging techniques other than electronic chromoendoscopy is not recommended for endoscopic surveillance at this time 
(conditional recommendation, very low level of evidence). 
  16. Endoscopic surveillance should employ four-quadrant biopsies at 2 cm intervals in patients without dysplasia and 1 cm intervals in patients with prior 
dysplasia (strong recommendation, low level of evidence). 
  17. Mucosal abnormalities should be sampled separately, preferably with endoscopic mucosal resection. Inability to perform endoscopic mucosal resection 
in the setting of BE with nodularity should lead to consideration to referral to a tertiary care center (strong recommendation, low level of evidence). 
  18. Biopsies should not be obtained in mucosal areas with endoscopic evidence of erosive esophagitis until after intensifi cation of antirefl ux therapy to 
induce mucosal healing (strong recommendation, very low level of evidence). 
  19. For BE patients with dysplasia of any grade, review by two pathologists, at least one of whom has specialized expertise in GI pathology, is warranted 
because of interobserver variability in the interpretation of dysplasia (strong recommendation, moderate level of evidence). 
  20. Use of additional biomarkers for risk stratifi cation of patients with BE is currently not recommended (strong recommendation, low level of evidence). 
  21. For BE patients without dysplasia, endoscopic surveillance should take place at intervals of 3 to 5 years (strong recommendation, moderate level of 
evidence). 
  22. Patients diagnosed with BE on initial examination do not require a repeat endoscopy in 1 year for dysplasia surveillance (conditional recommendation, 
very low level of evidence). 
  23. For patients with indefi nite for dysplasia, a repeat endoscopy after optimization of acid suppressive medications for 3–6 months should be performed. 
If the indefi nite for dysplasia reading is confi rmed on this examination, a surveillance interval of 12 months is recommended (strong recommendation, low 
level of evidence). 
  24. For patients with confi rmed low-grade dysplasia and without life-limiting comorbidity, endoscopic therapy is considered as the preferred treatment 
modality, although endoscopic surveillance every 12 months is an acceptable alternative (strong recommendation, moderate level of evidence). 
Table 1 continued on following page
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 Table 1 .  Continued 
  25. Patients with BE and confi rmed high-grade dysplasia should be managed with endoscopic therapy unless they have life-limiting comorbidity (strong 
recommendation, high level of evidence). 
 Therapy 
  Chemoprevention 
   26. Patients with BE should receive once-daily PPI therapy. Routine use of twice-daily dosing is not recommended, unless necessitated because of poor 
control of refl ux symptoms or esophagitis (strong recommendation, moderate level of evidence). 
   27. Aspirin or NSAIDs should not be routinely prescribed to patients with BE as an antineoplastic strategy. Similarly, other putative chemopreventive 
agents currently lack suffi cient evidence and should not be administered routinely (conditional recommendation, high level of evidence). 
  Endoscopic therapy 
   28. Patients with nodularity in the BE segment should undergo endoscopic mucosal resection of the nodular lesion(s) as the initial diagnostic and 
therapeutic maneuver (see point 17 above). Histologic assessment of the EMR specimen should guide further therapy. In subjects with EMR specimens 
demonstrating HGD, or IMC, endoscopic ablative therapy of the remaining BE should be performed (strong recommendation, high level of evidence). 
   29. In patients with EMR specimens demonstrating neoplasia at a deep margin, residual neoplasia should be assumed, and surgical, systemic, or ad-
ditional endoscopic therapies should be considered (strong recommendation, low level of evidence). 
   30. Endoscopic ablative therapies should not be routinely applied to patients with nondysplastic BE because of their low risk of progression to EAC (strong 
recommendation, very low level of evidence). Endoscopic eradication therapy is the procedure of choice for patients with confi rmed LGD, and confi rmed 
HGD, as noted above (see points 24 and 25). 
   31. In patients with T1a EAC, endoscopic therapy is the preferred therapeutic approach, being both effective and well tolerated (strong recommendation, 
moderate level of evidence). 
   32. In patients with T1b EAC, consultation with multidisciplinary surgical oncology team should occur before embarking on endoscopic therapy. In such 
patients, endoscopic therapy may be an alternative strategy to esophagectomy, especially in those with superfi cial (sm1) disease with a well-differentiated 
neoplasm lacking lymphovascular invasion, as well as those who are poor surgical candidates (strong recommendation, low level of evidence). 
   33. Routine staging of patients with nodular BE with EUS or other imaging modalities before EMR has no demonstrated benefi t. Given the possibility of 
over- and understaging, fi ndings of these modalities should not preclude the performance of EMR to stage-early neoplasia (Strong recommendation, 
moderate level of evidence). 
   34. In patients with known T1b disease, EUS may have a role in assessing and sampling regional lymph nodes, given the increased prevalence of lymph 
node involvement in these patients compared with less advanced disease (strong recommendation, moderate level of evidence). 
   35. In patients with dysplastic BE who are to undergo endoscopic ablative therapy for nonnodular disease, radiofrequency ablation is currently the 
preferred endoscopic ablative therapy (strong recommendation, moderate level of evidence). 
  Surgical therapy 
   36. Antirefl ux surgery should not be pursued in patients with BE as an antineoplastic measure. However, this surgery should be considered in those with 
incomplete control of refl ux symptoms on optimized medical therapy (strong recommendation, high level of evidence). 
   37. In cases of EAC with invasion into the submucosa, especially those with invasion to the mid or deep submucosa (T1b, sm2–3), esophagectomy, with 
consideration of neoadjuvant therapy, is recommended in the surgical candidate (strong recommendation, low level of evidence). 
   38. In patients with T1a or T1b sm1 adenocarcinoma, poor differentiation, lymphovascular invasion, or incomplete endoscopic mucosal resection should 
prompt consideration of surgical and/or multimodality therapies (strong recommendation, low level of evidence). 
 Management of BE after endoscopic therapy 
  39. Following successful endoscopic therapy and complete elimination of intestinal metaplasia (CEIM), endoscopic surveillance should be continued to 
detect recurrent IM and/or dysplasia (strong recommendation, low level of evidence). 
  40. Endoscopic surveillance following CEIM, for patients with HGD or IMC before ablation, is recommended every 3 months for the fi rst year following CEIM, 
every 6 months in the second year, and annually thereafter (conditional recommendation, low level of evidence). 
  41. In patients with LGD before ablation, endoscopic surveillance is recommended every 6 months in the fi rst year following CEIM, and annually thereafter 
(conditional recommendation, low level of evidence). 
  42. During endoscopic surveillance after CEIM, careful inspection of the tubular esophagus and gastroesophageal junction (in antegrade and retrograde 
views) should be performed with high-resolution white light imaging and narrow band imaging to detect mucosal abnormalities that may refl ect recurrent IM 
and/or dysplasia (strong recommendation, low level of evidence). 
  43. Treatment of recurrent metaplasia and/or dysplasia should follow guidelines for the treatment of metaplasia/dysplasia in BE before ablation (strong 
recommendation, low level of evidence). 
  44. Following CEIM, the goal of medical antirefl ux therapy should be control of refl ux as determined by absence of frequent refl ux symptoms (more than 
once a week) and/or esophagitis on endoscopic examination (conditional recommendation, very low level of evidence). 
 Endoscopic eradication therapy: training and education 
  45. Endoscopists who plan to practice endoscopic ablative procedures should additionally offer endoscopic mucosal resection (strong recommendation, 
very low level of evidence). 
 BE, Barrett’s esophagus; EAC, esophageal adenocarcinoma; EMR, endoscopic mucosal resection; EUS, endoscopic ultrasound; GER, gastroesophageal refl ux; GERD, 
gastroesophageal refl ux disease; GI, gastrointestinal; HGD, high-grade dysplasia; IM, intestinal metaplasia; IMC, intramucosal carcinoma; LGD, low-grade dysplasia; 
NSAID, nonsteroidal anti-infl ammatory drug; PPI, proton pump inhibitor. 
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be lower than the EGJ in the majority of patients, translating to 
short segments of CLE without IM. In a comparative study of the 
two methods performed in Japan, investigators concluded that the 
proximal extent of the gastric folds was more accurate compared 
with the palisade vessels ( 22 ). Th e diaphragmatic hiatus is identi-
fi ed as an indentation of the gastric folds that is apparent during 
upper endoscopy with inspiration.
 Any segment of BE measuring >3 cm has been classifi ed as 
long-segment BE, with segments <3 cm classifi ed as short-seg-
ment BE ( 23 ). It is recommended that a uniform classifi cation be 
used to facilitate diagnosis, but to date usage of a standard classifi -
cation system has not been demonstrated to change patient man-
agement. Th e Prague classifi cation, described initially in 2006, 
uses assessment of the circumferential and maximum extent of 
the endoscopically visualized BE segment as well as endoscopic 
landmarks ( Figure 1 ) ( 24 ). Applying this system prospectively, 
there were high reliability coeffi  cients (RCs) for recognition of BE 
segments  > 1 cm (RC 0.72), locations of the EGJ (RC 0.88), and 
diaphragmatic hiatus (RC 0.85), but not for BE segments <1 cm 
(RC 0.22). In addition to usage of the Prague classifi cation, it is 
recommended that all three landmarks, including the diaphrag-
matic hiatus, EGJ, and squamocolumnar junction, be mentioned 
in every endoscopic report. Isolated islands of columnar mucosa 
were not included in the Prague classifi cation and should be 
reported separately in the endoscopy report. Th ere are no data 
to suggest that a confi rmatory endoscopic examination is of 
utility in 1 year aft er diagnosis, as long as a suffi  cient number 
(up to 8) of biopsies are obtained during the initial examination 
from the Barrett’s segment ( 15 ). Th erefore, in situations where BE 
is suspected, we recommend acquiring 4 biopsies every 2 cm of 
segment length, or a total of at least 8 biopsies if the segment is 
<2 cm, at the initial exam.
 In patients with suspected BE on endoscopy without con-
fi rmation of IM despite adequate number of biopsies, a repeat 
examination could be considered in 1–2 years of time based on 
a longitudinal cohort study demonstrating that ∼ 30% of these 
patients can be expected to demonstrate IM on a repeat examina-
tion ( 25 ).
 EPIDEMIOLOGY AND NATURAL HISTORY OF BE
 Summary statements
 What are the risk factors for BE?
 1 .  Th e known risk factors for the presence of BE include the 
following: 
 a .  Chronic (>5 years) GERD symptoms 
 b .  Advancing age (>50 years) 
 c .  Male gender 
 d .  Tobacco usage 
 e .  Central obesity 
 f .  Caucasian race 
 2 .  Alcohol consumption does not increase risk of BE. Wine 
drinking may be a protective factor. 
 3 .  BE is more common in fi rst-degree relatives of subjects with 
known BE. 
 What are the risk factors associated with dysplasia and develop-
ment of EAC in patients with BE?
 1 .  Th e known risk factors for the development of neoplasia in 
BE include:
 a .  Advancing age 
 b .  Increasing length of BE 
 c .  Central obesity 
 d .  Tobacco usage 
 e .  Lack of nonsteroidal anti-infl ammatory agent use 
 f .  Lack of PPI use 
 g .  Lack of statin use. 
 What is the cancer risk in BE, based on degree of dysplasia?
 1 .  Th e risk of cancer progression for patients with nondysplastic 
is ∼ 0.2–0.5% per year. 
 2 .  For patients with low-grade dysplasia (LGD) the annual risk 
of progression to cancer is ∼ 0.7% per year. 
 3 .  For patients with high-grade dysplasia (HGD), the annual 
risk of neoplastic progression is ∼ 7% per year. 
 4 .  Th e majority (>90%) of patients diagnosed with BE die of 
causes other than EAC. 
 Summary of evidence
 Risk factors for BE .  BE has been detected in ∼ 15% of patients 
with chronic GERD ( 26 ) and in ∼ 1–2% of population subjects 
( Table 2 ) ( 27,28 ). In a population-based study from Sweden, the 
authors found that severe and chronic GERD were risk factors 
for the development of EAC; however, 40% of the cohort with 
esophageal cancer reported no prior history of GERD symp-
toms ( 29 ). In subjects with GERD, symptom duration has been 
shown to be a risk factor for the presence of BE. In a cohort study 
 Figure 1 .  Illustration of Prague Classifi cation for Barrett’s esophagus (BE) 
where C indicates circumferential extent of metaplasia and M indicates 
maximal extent of metaplasia. Schema shows a C2M5 segment with 
identifi cation of the gastroesophageal junction (GEJ) below the squamo-
columnar junction. Reprinted with permission ( 24 ).
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of onset of GERD symptoms may also be associated with BE. In a 
VA study, patients reporting frequent (defi ned as at least weekly) 
GERD symptoms starting before the age of 30 years had the high-
est risk of BE (OR 15.1, 95% CI 7.91–28.8), and risk increased 
linearly with earlier age at onset of symptoms ( P =0.001). Th e risk 
of BE also increased with cumulative GERD symptom duration 
( P =0.002) ( 32 ).
 Male gender has been consistently identifi ed as a risk factor for 
BE and EAC. A meta-analysis demonstrated an overall pooled male/
female ratio of 2:1 (95% CI 1.8–2.2) ( 33 ). Th e risk of development of 
EAC is also signifi cantly higher in men. In a study using the SEER 
(Th e Surveillance, Epidemiology, and End Results) database, women 
composed only 12% of all EACs. In this study, the risk of EAC in 
women with GERD symptoms was approximately equivalent to the 
risk of breast cancer in men (3.9 per 100,0000 at age 60 years) ( 34 ).
 Tobacco usage has been demonstrated to be a risk factor for 
BE in a recent meta-analysis based on 39 studies and 7,069 BE 
examining duration of GERD symptoms and risk for BE ( 30 ), 77 
(11%) of 701 patients with GERD symptoms were found to have 
BE on upper endoscopy. Compared with patients with GERD 
symptoms for <1 year, the odds ratio (OR) for BE increased to 3.0 
(95% confi dence interval (CI) 1.2–8.0) and 6.4 (95% CI 2.4–17.1) 
when symptoms were present for >5 and >10 years, respectively. 
A meta-analysis further demonstrated that the OR for the associ-
ation of GERD symptoms and BE was 2.9 (95% CI 1.9–4.5) with 
signifi cant heterogeneity between studies. When stratifi ed by 
length of BE, the heterogeneity resolved, demonstrating a strong 
association between GERD and long-segment BE (OR 4.9, 95% 
CI 2–12) but no association with short-segment BE (OR 1.2, 95% 
CI 0.8–1.7) ( 31 ).
 Increasing age is a risk factor for BE. In a retrospective study 
using the CORI (Clinical Outcomes Research Initiative) data-
base, the yield of BE in white men with GERD was 2% in the third 
decade of life, but increased to 9% in the sixth decade ( 4 ). Early age 
 Table 2 .  Risk factors for BE (estimates drawn from meta-analyses where available) 
 Risk factor  OR (95% CI)  Reference 
 Age (per 10-year increment)  1.53 (1.05–2.25)  Rubenstein  et al. ( 5 ) a 
  1.96 (1.77–2.17)  Cook  et al. ( 33 ) 
 Race/ethnicity 
 AA vs. Caucasian ethnicity  0.34 (0.12–0.97)  Abrams  et al. ( 49 ) 
 Hispanic vs. Caucasian ethnicity  0.38 (0.18–0.84)  Abrams  et al. ( 49 ) b 
 Hispanic vs. Caucasian ethnicity  1.1 (0.4–2.7)  Keyashian  et al. ( 50 ) c 
 GERD symptoms 
 Frequency (weekly vs. less frequent)  2.33 (1.34–4.05)  Rubenstein  et al. ( 5 ) a 
 Duration (>5 years vs. <1 year)  3.0 (1.2–8.0)  Lieberman  et al. ( 30 ) 
 Age of onset (weekly symptoms, <30 years vs. later)  31.4 (13.0–75.8)  Thrift  et al. ( 32 ) 
 Obesity 
 Overall  1.98 (1.52–2.57)  Singh  et al. ( 3 ) d 
 Increased WC  1.58 (1.25–1.99)  Singh  et al. ( 3 ) 
 Increased WHR  2.04 (1.49–2.81)  Singh  et al. ( 3 ) 
 Smoking 
 Current/past use vs. never  1.44 (1.20–1.74)  Andrici  et al. ( 35 ) 
 Pack years of cigarette use  1.99 (1.21–3.29)  Cook  et al. ( 196 ) 
 Family history 
 (BE, EAC, or GEJAC in fi rst- or second-degree relative)  12.23 (3.34–44.76)  Chak  et al. ( 42 ) 
 Hiatal hernia (overall)  3.94 (3.02–5.13)  Andrici  et al. ( 197 ) 
 Short-segment BE  2.87 (1.75–4.7)  Andrici  et al. ( 197 ) 
 Long-segment BE  12.67 (8.33–19.25)  Andrici  et al. ( 197 ) 
 AA, African American; BE, Barrett’s esophagus; CI, confi dence interval; EAC, esophageal adenocarcinoma; GEJAC, gastroesophageal junction adenocarcinoma; GERD, 
gastroesophageal refl ux disease; OR, odds ratio; WC, waist circumference; WHR, waist–hip ratio. 
 a In men only. 
 b In Hispanics from Dominican Republic. 
 c In Hispanics from Mexico. 
 d GERD and BMI independent association. 
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 Table 3 .  Cancer risk based on degree of dysplasia 
 Dysplasia type  Studies/patients  Incidence  95% CI  References 
 ND to EAC  57 Studies, 11,434 patients 
 50 Studies, 14,109 patients 
 3.3/1,000 person-years 
 6.3/1,000 person-years 
 2.8–3.8 
 4.7–8.4 
 ( 60 )
( 65 ) 
 ND to EAC or HGD  602 patients  4.8/1,000 person-years  0.3–7.8  ( 198 ) 
 LGD to EAC  24 Studies, 2,694 patients  5.4/1,000 person-years  3–8  ( 61 ) 
 LGD to EAC or HGD  17 Studies, 1,064 patients  173/1,000 person-years  100–250  ( 61 ) 
 HGD to EAC  4 Studies, 236 patients  7/100 patient-years  5–8  ( 62 ) 
 CI, confi dence interval; EAC, esophageal adenocarcinoma; HGD, high-grade dysplasia; LGD, low-grade dysplasia; ND, nondysplastic. 
patients. Any smoking during a patient’s lifetime was associated 
with a greater risk for BE compared with non-GERD controls 
(OR 1.4, 95% CI 1.2–1.7), but not when compared with patients 
with chronic GERD (OR 1.2, 95% CI 0.8–1.9), suggesting that the 
increased risk of BE associated with tobacco usage may be medi-
ated via increasing GERD ( 35 ).
 In contrast to tobacco usage, alcohol consumption has not been 
demonstrated to be signifi cantly associated with the risk for devel-
opment of BE ( 36,37 ). In fact, there are data suggesting a possible 
protective eff ect of wine consumption, with ORs ranging from 0.44 
(95% CI 0.2–0.99) to 0.71 (95% CI 0.52–0.98) ( 37,38 ).
 Th e presence of obesity is an independent risk factor for BE 
and EAC ( 39 ). However, it appears that a central pattern of obe-
sity, rather than overall body fat content (measured by BMI), is 
the primary risk factor for BE. In a meta-analysis ( 3 ), patients with 
central adiposity had a higher risk for BE compared with patients 
with normal body habitus (OR 2.0, 95% CI 1.5–2.6) and this rela-
tionship persisted aft er adjustment for BMI and GERD, suggesting 
a refl ux independent role for central obesity in BE pathogenesis. 
Indeed, overall body fat content is not associated with BE risk ( 40 ). 
Central obesity is a risk factor for BE in both men and women ( 41 ).
 Th e presence of a family history of BE has been identifi ed as 
another potential risk factor for BE ( 42 ). A cohort study demon-
strated that BE was markedly more common in fi rst- or second-
degree relatives of subjects with BE compared with controls (24% 
vs. 5%,  P <0.005). Aft er adjusting for age, gender, and body mass 
index, the presence of family history was strongly associated with 
BE (OR 12, 95% CI 3.3–44.8) ( 42 ). In a subsequent study, endo-
scopic screening was off ered to fi rst-degree previously uninvesti-
gated relatives of subjects with BE. Th e overall diagnostic yield was 
20% ( 43 ). Single-nucleotide polymorphisms on gene loci, which 
may confer increased susceptibility to BE development, have 
recently been described ( 44–47 ).
 Caucasian race appears to be a strong risk factor for BE. 
Although the evidence for lower prevalence of BE in African 
Americans compared with Caucasians is consistent ( 48,49 ), the 
results of studies comparing BE incidence in Hispanics and non-
Hispanic whites are inconsistent, likely refl ecting the heterogeneity 
of the Hispanic population ( 49,50 ).
 Other risk factors for BE have also been reported. Disease 
conditions such as metabolic syndrome ( 51 ), type 2 diabetes 
mellitus ( 52 ), and sleep apnea ( 53 ) have been identifi ed as poten-
tial BE risk factors.  H. pylori infection, particularly infection with 
Cag A+ strains, is associated with a decreased risk of BE in some 
studies ( 54,55 ).
 Risk factors associated with dysplasia and EAC in patients with 
BE .  Advancing age and increasing BE segment length are known 
risk factors for the presence of dysplasia in patients with BE. In 
a multicenter study of 309 BE patients (5 with cancer, 11 with 
HGD, and 29 with LGD), the risk factors for prevalent dysplasia 
included age (3.3% increase in dysplasia per year and BE segment 
length over 3 cm (risk increase of 14% per cm of BE present) ( 56 ).
 In patients with known BE, a variety of medications have been 
associated with reduced risk of progression to dysplasia and/or 
esophageal cancer including proton pump inhibitors (PPIs), aspi-
rin, nonsteroidal anti-infl ammatory agents, and statins. A meta-
analysis based on 7 studies with 2,813 patients demonstrated a 71% 
reduced risk of HGD and/or EAC with PPI users (OR 0.3, 95% CI 
0.1–0.8). No signifi cant eff ect was shown for H 2 RA usage in two 
studies ( 57 ). In another meta-analysis of 9 observational studies of 
5,446 participants (605 with HGD or EAC), usage of cyclooxyge-
nase inhibitors, aspirin, and nonaspirin cyclooxygenase inhibitors 
was associated with reduced risk for HGD and EAC independent of 
duration of therapy ( 58 ). By means of their antiproliferative, proa-
poptotic, antiangiogenic, and immunomodulatory eff ects, statins 
may prevent cancer development and growth. In a meta-analysis 
of 5 studies including 2,125 BE patients (312 EAC cases), statin 
usage was associated with a 41% reduction in EAC risk (adjusted 
OR 0.6, 95% CI 0.45–0.78) with the number needed to treat of 389 
to prevent 1 case of EAC ( 59 ).
 Cancer risk in BE based on degree of dysplasia .  A recent meta-
analysis published in 2012 demonstrated lower risk for progres-
sion of nondysplastic BE than previously reported ( Table 3 ) ( 60 ). 
It included 57 studies and demonstrated that the pooled annual 
incidence of EAC was 0.33% (95% CI 0.28–0.38%). In patients 
with short-segment BE reported from 16 studies, the annual can-
cer risk was 0.19%.
 For patients with LGD, a meta-analysis examined 24 studies. 
In this cohort, pooled annual incidence rates were 0.5% (95% CI 
0.3–0.8) for EAC alone and 1.7% (95% CI 1.0–2.5) for HGD and/
Diagnosis and Management of BE
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implications, such as the need for periodic endoscopic 
surveillance and therapy, if BE with dysplasia is diagnosed, 
should be discussed with the patient (strong recommenda-
tion, very low level of evidence). 
 11 .  Unsedated transnasal endoscopy (uTNE) can be considered 
as an alternative to conventional upper endoscopy for BE 
screening (strong recommendation, low level of evidence). 
 12 .  If initial endoscopic evaluation is negative for BE, repeating 
endoscopic evaluation for the presence of BE is not recom-
mended. If endoscopy reveals esophagitis (Los Angeles 
Classifi cation B, C, D), repeat endoscopic assessment aft er 
PPI therapy for 8–12 weeks is recommended to ensure heal-
ing of esophagitis and exclude the presence of underlying BE 
(conditional recommendation, low level of evidence). 
 Summary of evidence
 Survival of subjects diagnosed with EAC with regional or distant 
disease remains dismal, at <20% at 5 years ( 7 ). Th e concept of 
metaplasia–dysplasia–carcinoma progression sequence in BE 
has led to the hypothesis that screening for BE, institution of 
endoscopic surveillance to detect dysplasia, followed by endo-
scopic intervention, will lead to a decreased incidence of EAC 
( 66 ). In addition to detecting BE, screening also detects preva-
lent dysplasia or carcinoma that may be treated with endoscopic 
therapy. Th e available evidence to support this hypothesis, 
however, consists of retrospective studies that may be subject to 
biases. Indeed, >90% of EACs are diagnosed in patients without 
a prior BE diagnosis, despite the increasing use of endoscopy 
( 67,68 ).
 Given the number of patients involved, a widely embraced 
population screening eff ort could lead to substantial economic 
costs (from diagnostic tests and need for subsequent surveillance). 
Economic modeling studies ( 69 ) have found BE screening (done 
by endoscopy) followed by surveillance in hypothetical popula-
tions (50-year-old male subjects with GERD symptoms) to be 
cost eff ective, with acceptable incremental cost-eff ectiveness ratios 
ranging from $10,000 to 50,000/quality-adjusted life-year gained 
( 70,71 ). Estimates vary among studies, likely because of diff er-
ences in assumptions ( Supplementary Table S1 ). Th ree of these 
studies found that screening with video capsule endoscopy ( 72,73 ) 
or uTNE ( 74 ) was cost eff ective compared with no screening, but 
that standard endoscopy was preferred over capsule endoscopy. All 
assumed participation rates of almost 100% and accuracy rates of 
100%. Th is is likely an overestimate with lower participation rates 
(18–49%) ( 75–77 ), and lower accuracy rates for endoscopy (80%) 
being reported in prior studies ( 78 ). Of note, a substantial propor-
tion of BE diagnoses in the community are reversed, likely because 
of incorrect landmark identifi cation and incorrect targeting of 
biopsies ( 79 ). In addition, the yield of a repeat endoscopy following 
an initial negative endoscopy for BE is low (2.3%), with esophagitis 
and male gender being predictors of BE being diagnosed at sub-
sequent endoscopy ( 80 ). However, studies report a BE prevalence 
of 9–12% on repeat endoscopy following treatment of esophagitis 
with PPIs, making a repeat endoscopy aft er healing of more severe 
erosive esophagitis advisable ( 81,82 ).
or EAC combined ( 61 ). However, there was considerable hetero-
geneity in these results and when stratifi ed by the LGD/BE ratio as 
a surrogate for pathology quality, the incidence rate for EAC was 
0.76% per year for a ratio of <0.15 and 0.32% per year for a ratio 
of >0.15. Th is fi nding suggests that in settings where the diagnosis 
of LGD is made more liberally, and perhaps overcalled, there is a 
lower risk of progression.
 Th e risk of EAC for patients with HGD was examined in a 
meta-analysis of 4 studies and 236 patients. Th e weighted annual 
incidence rate was 7% (95% CI 5–8) ( 62 ). However, the AIM-Dys-
plasia trial that randomized 127 patients with dysplasia to ablation 
therapy compared with surveillance reported a much higher yearly 
progression rate of 19% in the HGD surveillance arm ( 63 ). Th is 
rate is similar to a second randomized trial that also required con-
fi rmation of HGD by a second expert pathologist, again suggesting 
that the rigor with which the histology is validated likely predicts 
the subsequent EAC risk ( 64 ).
 What are the common causes of death in subjects with BE? 
 Most BE patients die of other causes than EAC. A meta-analysis 
reported mortality rates from 19 studies in 7,930 patients ( 65 ). 
Th ere were 88 deaths because of EAC and 1,271 deaths because of 
other causes, resulting in a pooled incidence rate of fatal EAC of 
3/1,000 person-years (95% CI 2–4). In 12 studies reporting cause-
specifi c mortality, 7% of deaths (64/921) were from EAC, and 93% 
(857/921) because of other causes. Th e most common causes in-
cluded cardiac disease in 35%, followed by pulmonary disease in 
20% and other malignancies in 16% of the cohort.
 SCREENING FOR BE
 Recommendations 
 7 .  Screening for BE may be considered in men with chronic 
(>5 years) and/or frequent (weekly or more) symptoms of 
gastroesophageal refl ux (heartburn or acid regurgitation) and 
two or more risk factors for BE or EAC. Th ese risk factors 
include: age >50 years, Caucasian race, presence of central 
obesity (waist circumference >102 cm or waist–hip ratio 
>0.9), current or past history of smoking, and a confi rmed 
family history of BE or EAC (in a fi rst-degree relative) 
(strong recommendation, moderate level of evidence). 
 8 .  Given the substantially lower risk of EAC in females with 
chronic GER symptoms (when compared with males), 
screening for BE in females is not recommended. However, 
screening could be considered in individual cases as de-
termined by the presence of multiple risk factors for BE or 
EAC (age >50 years, Caucasian race, chronic and/or fre-
quent GERD, central obesity: waist circumference >88 cm, 
waist–hip ratio >0.8, current or past history of smoking, and 
a confi rmed family history of BE or EAC (in a fi rst-degree 
relative)). (strong recommendation, low level of evidence). 
 9 .  Screening of the general population is not recommended 
(conditional recommendation, low level of evidence). 
 10 .  Before screening is performed, the overall life expectancy 
of the patient should be considered, and subsequent 
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 SURVEILLANCE OF BE
 Recommendations 
 13 .  Patients should only undergo surveillance aft er adequate 
counseling regarding risks and benefi ts of surveillance 
(strong recommendation, very low level of evidence). 
 14 .  Surveillance should be performed with high-defi nition/high-
resolution white light endoscopy (strong recommendation, 
low level of evidence). 
 15 .  Routine use of advanced imaging techniques other than 
electronic chromoendoscopy is not recommended for endo-
scopic surveillance at this time (conditional recommenda-
tion, very low level of evidence). 
 16 .  Endoscopic surveillance should employ four-quadrant biop-
sies at 2 cm intervals in patients without dysplasia and 1 cm 
intervals in patients with prior dysplasia (strong recommen-
dation, low level of evidence). 
 17 .  Mucosal abnormalities should be sampled separately, prefer-
ably with endoscopic mucosal resection (EMR). Inability to 
perform EMR in the setting of BE with nodularity should 
lead to referral to a tertiary care center (strong recommenda-
tion, low level of evidence). 
 18 .  Biopsies should not be obtained in mucosal areas with endo-
scopic evidence of erosive esophagitis until aft er intensifi ca-
tion of antirefl ux therapy to induce mucosal healing (strong 
recommendation, very low level of evidence). 
 19 .  For BE patients with dysplasia of any grade, review by two 
pathologists, at least one of whom has specialized expertise in 
gastrointestinal (GI) pathology, is warranted because of 
interobserver variability in the interpretation of dysplasia 
(strong recommendation, moderate level of evidence). 
 20 .  Use of additional biomarkers for risk stratifi cation of patients 
with BE is currently not recommended (strong recommenda-
tion, low level of evidence). 
 21 .  For BE patients without dysplasia, endoscopic surveillance 
should take place at intervals of 3 to 5 years (strong recom-
mendation, moderate level of evidence). 
 22 .  Patients diagnosed with BE on initial examination with 
adequate surveillance biopsies do not require a repeat endo-
scopy in 1 year for dysplasia surveillance (conditional 
recommendation, very low level of evidence). 
 23 .  For patients with indefi nite for dysplasia, a repeat endoscopy 
aft er optimization of acid suppressive medications for 3–6 
months should be performed. If the indefi nite for dysplasia 
reading is confi rmed on the repeat examination, a surveil-
lance interval of 12 months is recommended (strong recom-
mendation, low level of evidence). 
 24 .  For patients with confi rmed LGD and without life-limiting 
comorbidity, endoscopic therapy is considered as the 
preferred treatment modality, although endoscopic surveil-
lance every 12 months is an acceptable alternative (strong 
recommendation, moderate level of evidence). 
 25 .  Patients with BE and confi rmed HGD should be managed 
with endoscopic therapy unless they have life-limiting 
comorbidity (strong recommendation, high level of 
evidence). 
 BE screening has several challenges. Although symptomatic 
GERD is a risk factor for BE and EAC, it is neither a sensitive nor 
specifi c marker ( 29,31 ). Only 5–15% of subjects with chronic (>5 
years) and frequent (weekly or more frequent) refl ux have BE ( 83 ), 
and as many as 50% of subjects with BE or EAC do not report 
chronic refl ux symptoms ( 31,84 ). Several studies have reported 
a substantial prevalence of BE in those without refl ux symptoms 
( 27,85,86 ). Indeed, although refl ux symptoms are associated with 
long-segment BE, they may not be consistently associated with 
short-segment BE ( 31 ). Hence, a BE screening strategy based 
solely on GERD symptoms is likely to be unsuccessful. Women 
(even those with daily or weekly refl ux symptoms) have a low inci-
dence of EAC comparable to that of men without refl ux symptoms 
( 34 ). Th is may relate to the lower risk of progression to EAC in 
women with BE compared with men with BE ( 60,87 ) and should 
likely infl uence the threshold of BE screening in women.
 Recent reports have described the creation of prediction or risk 
scores for BE using a combination of risk factors ( 5,88 ). Th is may 
enable the synthesis of multiple risk factors into a single clinically 
applicable parameter and make BE screening more effi  cient by 
targeting a high-risk target population. Accuracy for BE predic-
tion, though improved from GERD-only models, remains modest 
(area under the curve 0.73–81), but is likely to be improved by the 
addition of other variables such as circulating cytokine levels ( 89 ). 
Validation in larger unselected populations will be critical before 
widespread use.
 Several techniques are available for BE screening. Conventional 
endoscopy is regarded as the gold standard despite evidence on 
limitations of accuracy. uTNE as an alternate modality for BE 
screening has been found to have comparable performance char-
acteristics to endoscopy for the diagnosis of BE (sensitivity 98% 
and specifi city 100%) ( 90 ). Th e feasibility and safety of uTNE in BE 
screening in the community has also been demonstrated ( 75,77 ). 
Esophagoscopes with disposable sheaths, eliminating the need for 
standard disinfection, may be a viable alternative for BE screen-
ing ( 91 ). Although inability to intubate the nasopharynx and dis-
comfort are limitations of TNE, they occur in a small proportion 
of subjects, and a substantial majority are willing to undergo the 
procedure again. Nonphysician providers can be trained to per-
form this procedure, reducing costs further ( 92 ). Esophageal video 
capsule endoscopy is a well-tolerated, patient-preferred, and non-
invasive technique that allows visualization of the distal esophagus. 
However, because of inadequate accuracy (pooled sensitivity 78% 
and specifi city 73%) ( 93 ), it is currently not recommended for BE 
screening. More recently, a novel gelatin-coated sponge attached 
to a string that expands to a sphere when swallowed, and is then 
pulled out, obtaining esophageal cytology samples (Cytosponge), 
has been described. When combined with a protein marker, trefoil 
factor 3, a sensitivity of 73% and specifi city of 94% for BE diagno-
sis has been described ( 76 ). Although participation rates were low 
(18%), the device was overall safe and well tolerated. Given its non-
endoscopic nature, this device may allow cheaper, more conveni-
ent, offi  ce-based screening for BE if validated in subsequent studies. 
Th is method has also been shown to be cost eff ective compared 
with no screening or sedated endoscopy in a modeling study ( 94 ).
Diagnosis and Management of BE
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 Summary of the evidence
 Rationale for surveillance .  Survival in EAC is stage dependent 
and early spread before the onset of symptoms is characteristic of 
this tumor. Lymph node metastases are a clear prognostic factor 
for decreased survival ( 95 ). Th us, the best hope for improved sur-
vival of patients with EAC remains detection of cancer at an early 
and potentially curable stage.
 A number of observational studies suggest that patients with 
BE in whom EAC was detected in a surveillance program have 
their cancers detected at an earlier stage with markedly improved 
survival compared with similar patients not undergoing routine 
endoscopic surveillance ( 96–99 ). Furthermore, nodal involvement 
is far less likely in surveyed patients compared with nonsurveyed 
patients. As esophageal cancer survival is stage dependent, these 
studies suggest that survival may be enhanced by endoscopic 
surveillance. Recent work from a large Dutch population-based 
cohort study confi rmed that there is a survival advantage for EAC 
in patients who received adequate endoscopic surveillance com-
pared with patients who were not participating in endoscopic 
surveillance ( 100 ). Similarly, a large Northern Ireland population-
based study found that in patients with EAC and a prior diagnosis 
of BE, survival was enhanced, tumor stage was lower, and tumor 
grade was lower compared with patients without a prior diagno-
sis ( 101 ). Importantly, these fi ndings were maintained, although 
attenuated, aft er attempting to correct for both lead time and 
length time bias. On the other hand, a case–control study from the 
Northern California Kaiser Permanente population found no evi-
dence that endoscopic surveillance improved survival from EAC 
( 102 ). Although there are no prospective clinical trial data that 
demonstrate a benefi t of endoscopic surveillance, the considerable 
heterogeneity of available evidence makes it prudent to continue to 
perform endoscopic surveillance of BE patients.
 It is important to recognize, however, that endoscopic surveil-
lance, as currently practiced, has numerous shortcomings. Dys-
plasia may not be visible endoscopically and the distribution of 
dysplasia and cancer is highly variable. Even the most thorough 
biopsy surveillance program has the potential for sampling error. 
Current surveillance programs are expensive and time consuming. 
It is well known that adherence to practice guidelines is problem-
atic at best and worsens with longer segment lengths ( 103 ). All of 
these shortcomings likely diminish any benefi t from these pro-
grams, and eff orts to adhere to published standards for the per-
formance of various elements of surveillance are recommended.
 Counseling for surveillance .  Before entering into a surveil-
lance program, patients should be counseled about the risks and 
benefi ts of this program, including the limitations of surveillance 
endoscopy as well as the importance of adhering to appropriate 
surveillance intervals. Other considerations include age, likeli-
hood of survival over the next 5 years, and ability to tolerate 
interventions including endoscopic therapy, surgery, and medical 
or radiation oncologic treatments for EAC.
 Until recently, the concept of early outpatient consultation to 
review the signifi cance of BE has not been a point of emphasis in 
prior practice guidelines ( 10 ). Why is this important? First, wide 
access to the Internet allows patients to obtain information about 
BE and EAC in an unfi ltered manner. Studies to date suggest that 
patients both over- and under-estimate their cancer risk ( 16,104 ). 
Given the low risk of progression to cancer for most patients with 
BE and the data suggesting that most BE patients die of causes 
other than EAC, such counseling should now be part of the ongo-
ing care of these patients to help inform decision making regarding 
therapeutic options ( 65 ).
 Surveillance technique .  Endoscopic surveillance should utilize 
high-resolution/high-defi nition white light endoscopy to opti-
mize visualization of mucosal detail. Recent work suggests that 
this is superior to standard-defi nition white light endoscopy for 
the detection of dysplastic lesions ( 105 ). Th is should be accom-
panied by removal of any mucosal debris and careful insuffl  ation 
and desuffl  ation of the lumen. Part of the examination should also 
incorporate a retrofl exed view of the GEJ. Data demonstrate a di-
rect correlation between inspection time of the Barrett’s segment 
and detection of patients with HGD/EAC ( 106 ). Inspection of the 
Barrett’s segment should also involve careful attention to the right 
hemisphere of the segment, extending from the 12 o’clock to 6 
o’clock location where early cancer appears to have a predilection 
to develop ( 107,108 ).
 Th e aim of surveillance is detection of dysplasia. Th e descrip-
tion of dysplasia should use a standard fi ve-tier system: (i) nega-
tive for dysplasia, (ii) indefi nite for dysplasia, (iii) LGD, (iv) HGD, 
and (v) carcinoma ( 109 ). Active infl ammation makes it more dif-
fi cult to distinguish dysplasia from reparative changes. As such, 
surveillance biopsies should only be performed aft er any active 
infl ammation related to GERD is controlled with antisecretory 
therapy. Th e presence of ongoing erosive esophagitis is a relative 
contraindication to performing surveillance biopsies. Once any 
infl ammation related to GERD is controlled with antisecretory 
therapy, systematic four-quadrant biopsies at 2 cm intervals along 
the entire length of the Barrett’s segment remains the standard for 
endoscopic surveillance of nondysplastic BE.
 A systematic biopsy protocol clearly detects more dysplasia and 
early cancer compared with  ad hoc random biopsies ( 110,111 ). 
Subtle mucosal abnormalities, no matter how trivial, such as ulcer-
ation, erosion, plaque, nodule, stricture, or other luminal irregular-
ity in the Barrett’s segment, should also be sampled, as there is an 
association of such lesions with underlying cancer ( 112 ). Mucosal 
abnormalities, encountered in the setting of surveillance of patients 
with known dysplasia, should undergo EMR. EMR will change the 
diagnosis in ∼ 50% of patients when compared with endoscopic 
biopsies, given the larger tissue sample available for review by the 
pathologist ( 113 ). Interobserver agreement among pathologists is 
improved as well ( 114 ). Th e safety of systematic endoscopic biopsy 
protocols has been demonstrated ( 115 ). Th e addition of routine 
cytologic sampling to endoscopic biopsies appears to add little to 
surveillance biopsies ( 116 ). Th e role of computer-assisted or wide-
fi eld “brush biopsy” tissue acquisition for increasing the yield of 
dysplasia is currently under investigation ( 117,118 ). Currently, 
the fi nding of subsquamous BE on surveillance biopsies of the 
untreated patient does not change patient management, based on 
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the most advanced histology found on the combination of targeted 
and random biopsies.
 Advanced endoscopic imaging techniques .  A wide variety of 
enhancements to endoscopic imaging with white light endoscopy 
have been studied in recent years to allow for detailed inspection 
of the Barrett’s segment. Electronic chromoendoscopy allows for 
detailed imaging of the mucosal and vascular surface patterns in 
BE without the need for chromoendoscopy dye sprays. Th is may 
be accomplished with either narrow band imaging that uses opti-
cal fi lters to narrow the band width of white light to blue light 
or by postprocessing soft ware systems to accomplish similar visu-
alization. Most of the published literature to date have examined 
narrow band imaging in conjunction with magnifi cation endos-
copy. A randomized clinical trial of narrow band imaging vs. 
high-defi nition white light endoscopy demonstrated no diff erence 
in the number of patients detected with dysplasia or neoplasia. 
However, fewer biopsies were required for narrow band imaging 
( 119 ). A recent meta-analysis also suggests that electronic chro-
moendoscopy may increase detection of dysplasia ( 120 ). A wide 
variety of other image enhancement techniques have been stud-
ied including methylene blue staining, acetic acid staining, indigo 
carmine staining, autofl uorescence endoscopy, confocal laser en-
domicroscopy, volumetric laser endomicroscopy, spectroscopy, 
and molecular imaging, but none of these methods appear ready 
for widespread clinical use at present.
 Importance of confi rmation of dysplasia .  Dysplasia remains 
the best clinically available marker of cancer risk in patients with 
BE. However, there is considerable interobserver variability in the 
interpretation of dysplasia in both the community and academic 
settings. Th at being said, there is reasonable interobserver agree-
ment among GI pathologists for the extremes of dysplasia, namely 
IM without dysplasia and HGD/EAC ( 109 ). Th ere is considerably 
more diffi  culty in the interpretation of indefi nite for dysplasia and 
LGD ( 121 ). Th e importance of the confi rmation of the diagnosis 
of LGD comes from two recent studies from the Netherlands. 
Review by two GI pathologists, with extensive experience in 
the diagnosis of BE-related neoplasia, found that of 147 patients 
diag nosed with LGD in the community, 85% of the patients were 
downgraded to a diagnosis of no dysplasia ( 122 ). Further work by 
that group examined 293 additional patients with LGD diagnosed 
in the community who had biopsies reviewed by at least 2 GI 
pathologists and 73% of the cases were downgraded to indefi -
nite for dysplasia or nondysplastic BE ( 123 ). Other studies sug-
gest that community-based pathologists have diffi  culties in the 
interpretation of both nondysplastic BE and dysplasia ( 124 ). 
Th erefore, current evidence supports the importance of having 
all readings of dysplasia confi rmed by a second pathologist with 
extensive experience in the interpretation of Barrett’s associated 
neoplasia.
 Surveillance intervals .  Surveillance intervals are determined by 
the presence and grade of dysplasia and are currently governed 
by expert opinion. Given the low risk of progression of BE to 
EAC, surveillance at 3- to 5-year intervals remains reasonable in 
patients without dysplasia.
 Th ere is a paucity of data to guide the management of BE 
patients with biopsies indefi nite for dysplasia. It is reasonable 
to use double-dose PPI therapy to decrease any ongoing infl am-
mation. A retrospective study found that indefi nite for dyspla-
sia was associated with a similar risk of progression to cancer as 
was LGD ( 125 ). More recent data suggest an especially high risk 
of progression to higher grades of dysplasia within the fi rst year 
of diagnosis but a risk comparable to nondysplastic BE aft er the 
fi rst year ( 126 ). Th e progression risk may be more pronounced 
in multifocal indefi nite for dysplasia (defi ned as indefi nite for 
dysplasia in biopsies from more than one level of the esophagus) 
than in focal indefi nite for dysplasia ( 127 ). Th us, surveillance in 
these patients should follow the recommendations for LGD as 
described below.
 If LGD is found, the diagnosis should fi rst be confi rmed by a 
second pathologist with expertise in BE. Th ese patients should 
also receive aggressive antisecretory therapy for refl ux disease 
with a PPI to decrease the changes associated with regeneration or 
infl ammation. A repeat endoscopy aft er optimization of acid sup-
pressant therapy may result in downgrading of the LGD reading. If 
LGD is confi rmed and endoscopic therapy not performed, annual 
surveillance is recommended until two examinations in a row are 
negative for dysplasia, aft er which time surveillance intervals for 
nondysplastic BE can be followed. A protocol of four-quadrant 
biopsies at 1 cm intervals is advisable, given that anatomic studies 
suggest that dysplasia can occur in a mosaic pattern and involve 
small portions of the overall surface area of the esophagus. EMR 
should be performed if any mucosal abnormality is present in 
these patients.
 If HGD is found, the diagnosis should fi rst be confi rmed by a 
second pathologist with experience in GI pathology. Th e presence 
of any mucosal abnormality warrants EMR in an eff ort to 
maximize staging accuracy. If HGD is confi rmed, endoscopic 
intervention is warranted as described below.  Figure 2 demon-
strates the recommended actions for surveillance endoscopy of 
nonnodular BE.
 Biomarkers of increased risk .  Given the limitations of endoscopic 
surveillance and histologic dysplasia as a risk stratifi cation tool, 
molecular markers to identify patients at increased risk for pro-
gression have been studied. Abnormalities including DNA con-
tent abnormalities, chromosomal abnormalities, gene mutations, 
methylation changes, and clonal diversity measurements defi ne 
patients at increased risk for progression to cancer ( 128–132 ). 
Th ese genetic abnormalities appear to occur early in disease 
development ( 133 ).
 Recent promising work in a case–control study suggested that 
aberrant p53 expression defi ned as absent or increased expression 
by immunohistochemistry was associated with an increased risk 
of neoplastic progression ( 134 ). However, it appears that no sin-
gle biomarker is adequate as a risk stratifi cation tool. Given the 
complexity and diversity of alterations observed to date in the pro-
gression sequence, a panel of biomarkers may be required for risk 
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apy. In subjects with EMR specimens demonstrating HGD, 
or intramucosal carcinoma, endoscopic ablative therapy of 
the remaining BE should be performed (strong recommen-
dation, high level of evidence). 
 29 .  In patients with EMR specimens demonstrating neoplasia at 
a deep margin, residual neoplasia should be assumed, and sur-
gical, systemic, or additional endoscopic therapies should be 
considered (strong recommendation, low level of evidence). 
 30 .  Endoscopic ablative therapies should not be routinely applied 
to patients with nondysplastic BE because of their low risk 
of progression to EAC (strong recommendation, very low 
level of evidence). Endoscopic eradication therapy is the 
procedure of choice for patients with confi rmed LGD, and 
confi rmed HGD, as noted above (see points 24 and 25). 
 31 .  In patients with T1a EAC, endoscopic therapy is the preferred 
therapeutic approach, being both eff ective and well tolerated 
(strong recommendation, moderate level of evidence). 
 32 .  In patients with T1b EAC, consultation with multidiscipli-
nary surgical oncology team should occur before embarking 
on endoscopic therapy. In such patients, endoscopic therapy 
may be an alternative strategy to esophagectomy, especially in 
those with superfi cial (sm1) disease with a well-diff erentiated 
neoplasm lacking lymphovascular invasion, as well as those 
who are poor surgical candidates (strong recommendation, 
low level of evidence). 
stratifi cation. At the present time, no biomarkers or panels of bio-
markers are ready for clinical practice. In order to become part of 
the clinical armamentarium, biomarkers will have to be validated 
in large prospective cohorts. Such studies will be challenging given 
the low overall progression of BE to HGD/EAC.
 THERAPY
 Recommendations 
 Chemoprevention . 
 26 .  Patients with BE should receive once-daily PPI therapy. Routine 
use of twice-daily dosing is not recommended, unless necessi-
tated because of poor control of refl ux symptoms or esophagitis 
(strong recommendation, moderate level of evidence). 
 27 .  Aspirin or nonsteroidal anti-infl ammatory drugs should not 
be routinely prescribed to patients with BE as an antineo plastic 
strategy. Similarly, other putative chemopreventive agents cur-
rently lack suffi  cient evidence and should not be administered 
routinely (conditional recommendation, high level of evidence). 
 Endoscopic therapy . 
 28 .  Patients with nodularity in the BE segment should undergo 
EMR of the nodular lesion(s) as the initial diagnostic and 
therapeutic maneuver (see point 17 above). Histologic 
assessment of the EMR specimen should guide further ther-
 Figure 2 .  Management of nonnodular Barrett’s esophagus (BE). *Although endoscopic eradication therapy is associated with a decreased rate of 
progression, surveillance upper endoscopy at 1-year intervals is an acceptable alternative. The above schema assumes that the T1a esophageal adeno-
carcinoma (EAC) displays favorable characteristics for endoscopic therapy, including well-differentiated histology and lack of lymphovascular invasion. 
EGD, esophagogastroduodenoscopy; HGD, high-grade dysplasia; LGD, low-grade dysplasia; PPI, proton pump inhibitor. 
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 33 .  Routine staging of patients with nodular BE with endoscopic 
ultrasound (EUS) or other imaging modalities before EMR 
has no demonstrated benefi t. Given the possibility of over-
staging and understaging, fi ndings of these modalities should 
not preclude the performance of EMR to stage early neoplasia 
(strong recommendation, moderate level of evidence). 
 34 .  In patients with known T1b disease, EUS may have a role 
in assessing and sampling regional lymph nodes, given the 
increased prevalence of lymph node involvement in these 
patients compared with less advanced disease (strong recom-
mendation, moderate level of evidence). 
 35 .  In patients with dysplastic BE who are to undergo endoscopic 
ablative therapy for nonnodular disease, radiofrequency abla-
tion is currently the preferred endoscopic ablative therapy 
(strong recommendation, moderate level of evidence). 
 Surgical therapy . 
 36 .  Antirefl ux surgery should not be pursued in patients with BE 
as an antineoplastic measure. However, this surgery should 
be considered in those with incomplete control of refl ux on 
optimized medical therapy (strong recommendation, high 
level of evidence). 
 37 .  In cases of EAC with invasion into the submucosa, especially 
those with invasion to the mid or deep submucosa (T1b, 
sm2–3), esophagectomy, with consideration of neoadjuvant 
therapy, is recommended in the surgical candidate (strong 
recommendation, low level of evidence). 
 38 .  In patients with T1a or T1b sm1 EAC, poor diff erentiation, 
lymphovascular invasion, or incomplete EMR should prompt 
consideration of surgical and/or multimodality therapies 
(strong recommendation, low level of evidence). 
 Summary of evidence
 No aspect of these guidelines has evolved more since the last 
guideline iteration than therapeutic aspects of BE ( 135 ). Most 
profound of these changes is our markedly augmented ability to 
provide eff ective endoscopic therapy for subjects with neoplastic 
BE. Aspects of chemoprevention, endoscopic intervention, and 
surgical evaluation are discussed below.
 Chemoprevention .  Data substantiating a chemopreventive eff ect 
in the setting of BE are sparse. In part, this paucity of data refl ects 
the low rate of progression to neoplasia in BE ( 65,136 ), making in-
tervention studies diffi  cult to perform. In addition, patients who 
might have previously been considered for chemoprevention, 
such as those with BE and LGD, are now considered for endo-
scopic ablative therapy, making the pool of patients who would 
gain markedly from a chemopreventive agent even smaller.
 PPI therapy is common in patients with BE, in part because of 
the high proportion of those patients who also have symptomatic 
GERD. In these cases, the use of PPIs is substantiated by the need 
for symptom control, making consideration of chemoprevention 
secondary. However, even in patients without refl ux symptoms, in 
whom BE is incidentally found during evaluation of other symp-
toms and/or signs, the use of PPIs deserves consideration. Several 
cohort studies now suggest that subjects with BE maintained on 
PPI therapy have a decreased risk of progression to neoplastic BE 
compared with those with either no acid suppressive therapy or 
those maintained on H 2 RA therapy ( 57,137–139 ). In addition, the 
risk profi le of these medications is favorable in most patients, and 
the cost of this class of drugs has diminished substantially in recent 
years because of the availability of generic forms of the medica-
tions. Th ese factors, combined with the theoretical consideration 
that the same infl ammation that may be in part be responsible for 
pathogenesis of BE may also promote progression of BE, make 
the use of PPIs in this patient population appear justifi ed, even in 
those without GERD symptoms ( 57 ). Given the low probability 
of a randomized study of PPI use in BE, decisions regarding this 
intervention will likely rely on these retrospective data and expert 
opinion.
 Some indirect evidence also supports consideration of acetylsali-
cyclic acid (ASA) as a chemopreventive agent in BE. Patients taking 
ASA appear less likely to develop esophageal cancer in epidemio-
logical studies ( 140,141 ). In additionally, ASA and nonsteroidal 
anti-infl ammatory drugs may inhibit several pathways important 
in oncogenesis. However, unlike the case with PPIs, the side-eff ect 
profi le of ASA is not benign, and adverse events including cerebral 
and GI hemorrhage may be catastrophic. Also, given recent level 1 
evidence demonstrating markedly diminished cancer risk in sub-
jects with LGD undergoing endoscopic therapy ( 142 ), it is likely 
that more patients with confi rmed LGD will undergo this therapy, 
as opposed to surveillance endoscopy. If so, these patients will 
likely not need chemoprevention. Given that the risk of progres-
sion in patients with nondysplastic BE is so low, any chemopre-
ventive agent in this group of patients must be very safe to justify 
its use. While we await results from a trial randomizing patients 
with BE to ASA or placebo ( 143 ), the current data do not justify 
the routine use of ASA or other nonsteroidal anti-infl ammatory 
drugs in chemoprevention in BE. However, in the substantial pro-
portion of subjects with BE who are also candidates for ASA use 
for cardioprotection, additional benefi t may be derived from any 
chemoprotective eff ect of ASA on their BE.
 Endoscopic therapy .  Advances in endoscopic therapy in the past 
decade have broadened the pool of patients with BE who may 
be considered for intervention as well as diminished the need 
for esophagectomy in this patient population. Given the rapid 
evolution of these technologies, it is important that endoscopists 
apply evidence-based decision making with respect to the utiliza-
tion of these technologies.
 Consideration of any endoscopic therapy in BE begins with a 
close inspection of the BE mucosa. Th e identifi cation of mucosal 
irregularities including nodularity, ulceration, or fl at but irregu-
lar mucosal contour is essential to detecting the areas of highest 
yield for neoplasia. In this role, the adjunct use of a narrow light 
spectrum imaging technology, such as narrow band imaging, may 
aid in detecting mucosal irregularity ( 144 ). If such irregularity is 
detected, the next step in the management of that patient should 
be EMR or endoscopic submucosal dissection, both for therapeu-
tic benefi t and to allow staging of the lesion ( 145,146 ). Although 
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than previously believed ( 68,136,148 ). Given the low rate of pro-
gression in these patients, the low but real rate of complications of 
endoscopic therapy ( 149 ), and the costs associated with its delivery 
( 150 ), ablative therapy cannot be recommended in patients with 
nondysplastic BE. Whether these therapies are warranted in sub-
jects judged to have a higher lifetime risk of cancer, such as those 
with familial BE/EAC and young patients with long segments of 
BE, is unclear ( 151–153 ).
 In patients with EAC, depth of invasion decides the curative 
potential of endoscopic therapy ( Supplementary Figure S1 ). 
Lesions confi ned to the mucosa have a very low rate of lym-
phatic involvement ( 154,155 ), making these lesions optimally 
treated by mucosal resection, followed by a mucosal ablative 
therapy to eradicate the remaining BE. Lesions with superfi cial 
submucosal invasion (T1b sm1) have confl icting data with respect 
to the likelihood of lymph node invasion ( 146,156,157 ), making 
consideration of surgery and/or multimodality therapy appro-
priate. However, in subjects at high risk of complications with 
esophagectomy, endoscopic therapy can be considered as an alter-
native to more traditional treatments, and reported outcomes of 
highly selected patients are encouraging ( 146 ). If endoscopic ther-
apy is being considered for defi nitive therapy for such a patient, 
well-diff erentiated tumors, as well as those with no lymphovas-
cular invasion, have the best prognosis ( 154,155 ). Lesions with 
invasion into the mid or deep submucosa (T1b sm2 or T1b sm3) 
endoscopic submucosal dissection may provide a more complete 
understanding of the lateral margins of a lesion, it is technically 
more demanding, and should only be pursued in settings where 
the team has expertise in this maneuver. EMR is generally ade-
quate to reveal the depth of invasion, the most important variable 
in clinical decision making.
 Th e fi ndings of endoscopic resection determine subsequent 
management of the patient. In patients with a history of nondys-
plastic BE whose EMR demonstrates no dysplasia, surveillance 
endoscopy can be resumed. In subjects with LGD or HGD and 
complete resection of the lesion, the EMR should be generally fol-
lowed by endoscopic ablative therapy, with the goal of achieving 
complete eradication of all IM, and thereby decreasing the likeli-
hood of recurrent dysplasia.  Figure 3 demonstrates the manage-
ment of nodular BE.
 In patients with nonnodular BE, the utility of ablative therapy 
is becoming clearer. In patients with BE and HGD, ablative ther-
apy should be preferred over either esophagectomy or intensive 
endoscopic surveillance because of its proven effi  cacy ( 63 ) and a 
side-eff ect profi le superior to surgery ( 147 ). Recent data demon-
strate that in patients with BE and LGD confi rmed by a second 
pathologist, ablative therapy results in a statistically and clinically 
signifi cant reduction in progression to the combined end point of 
HGD or EAC, or to EAC alone ( 142 ). In contrast, in patients with 
nondysplastic BE, recent data suggest lower rates of progression 
 Figure 3 .  Management of nodular Barrett’s esophagus (BE). *Little data exist on the clinical course of patients with low-grade dysplasia (LGD) managed 
by endoscopic surveillance following endoscopic mucosal resection (EMR), although this is an alternative treatment strategy. Endoscopic submucosal 
dissection is an alternative to EMR. Favorable histology consists of no lymphatic or vascular invasion and moderate- to well-differentiated disease. EAC, 
esophageal adenocarcinoma. 
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are associated with high rates of lymphatic involvement ( 154,158 ). 
Endoscopic therapy performed on such lesions should be consid-
ered palliative. Currently, the added value of endoscopic therapy 
as part of a scheme of multimodality therapy (for instance, endo-
scopic therapy plus chemotherapy and/or radiotherapy) is not well 
described in the literature. However, because of the potential of 
such an approach to provide both local and systemic control of 
disease, further study is warranted.
 Th e role of imaging modalities such as EUS, positron emission 
tomography, and computed tomography scanning is becoming 
clearer. Data demonstrate that a substantial minority of patients 
with superfi cial EAC will be both over- and understaged by EUS 
( 159–161 ). Th erefore, the routine use of this modality before EMR 
is unwarranted, as clinical decision making will rest with the EMR 
fi ndings. EUS may have a limited role in endoscopic therapy of 
early esophageal neoplasia in the setting of T1b disease ( 162 ). For 
the subject being considered for endoscopic therapy with T1b dis-
ease, evidence of locoregional lymph node involvement, especially 
if substantiated by fi ne-needle aspiration, means any attempt at 
endoscopic therapy would be palliative, and that other modalities 
need be invoked for curative intent. Given the low likelihood of 
distant involvement in intramucosal (T1a) cancer or subjects diag-
nosed with dysplastic BE, positron emission tomography–com-
puted tomography has no demonstrated benefi t in these clinical 
settings. Positron emission tomography–computed tomography 
may have value aft er a diagnosis of T1b disease, in detecting dis-
tant involvement.
 EMR is not adequate as sole therapy for T1a or T1b EAC. Cohort 
studies document that up to one-third of patients treated with EMR 
who achieve complete resection of the primary lesion will subse-
quently develop recurrent HGD or EAC ( 145 ). Whether these 
subsequent lesions represent undetected metachronous lesions or 
a fi eld eff ect in the susceptible patient is unclear. However, endo-
scopic ablative treatment of the remainder of the BE markedly 
decreases this risk. Th erefore, all patients with successful resection 
of a T1a EAC, as well as any T1b lesions selected for endoscopic 
therapy, should undergo subsequent ablation of the remainder of 
the BE segment.
 Successful endoscopic ablative therapy is defi ned as complete 
eradication of all dysplasia, as well as all IM, in the tubular esopha-
gus. In order to demonstrate this outcome, biopsies in four quad-
rants at the GEJ, as well as every cm through the extent of previous 
BE, are taken. In addition, because several case series report occur-
rence of neoplasia in the cardia or at the GEJ following successful 
ablative therapy, surveillance biopsies of the cardia should be rou-
tinely performed ( 163 ). Because of the sampling error inherent in 
random biopsies, some authorities have suggested that two nega-
tive biopsy sessions be attained before declaring the patient to have 
achieved complete eradication ( 164 ). However, no objective data 
demonstrate an optimum defi nition of complete eradication, with 
respect to number of biopsy sessions free of disease.
 Th e decision of when to call a patient a “failure” of endoscopic 
ablative therapy depends on the clinical situation of the patient, 
the amount of progress made with initial attempts at ablation, and 
the likely mechanism of failure. Data from cohort studies show 
that even among patients who underwent four sessions of radio-
frequency ablation without complete eradication of IM (CEIM), 
>50% eventually attained this goal with subsequent therapy, 
suggesting that a concrete number cutoff  for failure is not advis-
able ( 165 ).
 As to the choice of ablative modalities in BE, a wide variety of 
modalities have been reported to be eff ective in the eradication 
of IM. Currently, level 1 evidence for prevention of cancer inci-
dence exists in three clinical scenarios: photodynamic therapy in 
the setting of BE with HGD, radiofrequency ablation in the set-
ting of HGD, and radiofrequency ablation in the setting of LGD 
( 63,142,166 ). Given the costs and side-eff ect profi le of photo-
dynamic therapy, as well as the large body of data supporting 
the safety and effi  cacy of radiofrequency ablation, this modality 
appears to be the preferred therapy for most patients. Th is recom-
mendation may change as further data become available. Promis-
ing cohort data on cryotherapy demonstrate high rates of CEIM 
and neoplasia ( 167,168 ).
 Surgical therapy .  Several studies have attempted to assess the 
relative value of surgical antirefl ux procedures in the prevention 
of EAC in the setting of BE. One relatively small randomized trial 
showed no diff erence in progression outcomes between medical 
and surgical groups ( 169 ), but this result is susceptible to type II 
error. Meta-analyses on the subject reveal confl icting results, in 
that some authors have found no diff erence in cancer risk bet-
ween medically and surgically managed patients, whereas others 
show some suggestion of improved outcomes in surgically treated 
patients ( 170–172 ). Given the weak nature of the data, along with 
the overall very low incidence of cancer in the setting of nondys-
plastic BE, antirefl ux surgery should not be considered as an anti-
neoplastic measure in the setting of BE. Th erefore, the indications 
for this procedure in BE patients are the same as those in gen-
eral GERD patients—principally GERD symptoms or esophagitis 
not well controlled by medical therapy. With respect to optimiz-
ing medical therapy, dosages of PPI beyond twice daily have not 
been demonstrated to have benefi cial eff ect in patients with BE. 
We recommend once-daily PPI therapy for patients with BE un-
less GERD symptoms require twice daily for adequate symptom 
control.
 In contrast, esophagectomy has a well-established role in the 
care of patients with BE and EAC. It is the treatment of choice for 
fi t candidates with T1b sm2–3 disease, either alone or in combi-
nation therapy with radiation and/or chemotherapy. Similarly, in 
patients with T1a or T1b sm1 EAC and unfavorable prognostic 
factors, such as poor diff erentiation or lymphovascular invasion, 
surgical consultation should be obtained.
 MANAGEMENT OF BE AFTER ENDOSCOPIC THERAPY
 Recommendations 
 39 .  Following successful endoscopic therapy and CEIM, endo-
scopic surveillance should be continued to detect recurrent 
IM and/or dysplasia (strong recommendation, low level of 
evidence). 
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ter. Most studies use four-quadrant biopsies every cm through-
out the previous BE segment with additional targeted biopsies 
of any endoscopic abnormality, although this approach has not 
been compared with other biopsy regimens. Th ere is currently 
no evidence to support discontinuing surveillance aft er multiple 
negative surveillance endoscopies, given reports of recurrent neo-
plasia several years aft er CEIM in cohort studies.
 Biopsies from the tubular esophagus and GEJ should be obtained 
in separate bottles to allow localization and treatment of recurrent 
BE. Th e optimal number of biopsies needed for adequate surveil-
lance is unknown. Despite concerns regarding depth of biopsies 
aft er ablation, the prevalence of subsquamous BE is variable aft er 
ablation, with rates ranging from 0.9% aft er RFA to 14.2% aft er 
photodynamic therapy ( 181 ). Imaging techniques such as optical 
coherence tomography suggest a higher prevalence of subsqua-
mous BE, particularly at the GEJ ( 182 ), but the signifi cance of this 
is unclear, despite case reports of subsquamous EACs arising aft er 
ablation ( 175 ). Some studies suggest that surveillance biopsies 
obtained aft er ablation may be too superfi cial to detect subsqua-
mous BE, with most biopsies not containing lamina propria ( 183 ). 
Th is has however not been confi rmed by other studies ( 184 ). It is 
unclear whether biopsies with large capacity forceps will be more 
eff ective at sampling deeper layers of the neosquamous epithe-
lium as compared with regular capacity biopsy forceps. Although 
neosquamous epithelium may be more permeable than normal 
squamous epithelium ( 185 ), it does not appear to harbor genetic 
abnormalities ( 186 ).
 Most recurrent metaplasia and dysplasia, when detected by sur-
veillance, is amenable to endoscopic therapy, including EMR and 
additional ablation ( 176,177,180 ). However, a few cases requiring 
esophagectomy for invasive carcinoma have been reported ( 187 ). 
Predictors of recurrence are not well defi ned, with some studies 
suggesting that older age, a longer preablation BE segment, pres-
ence of a larger hiatal hernia ( 188 ), and higher grade of dysplasia 
before ablation are associated with higher rates of recurrence ( 174 ).
 Th ere is some evidence from uncontrolled observational stud-
ies to suggest that incomplete control of refl ux may be associated 
with increased recurrence rates following successful endotherapy 
( 189,190 ). However, there is currently a lack of conclusive evidence 
to suggest that high-dose PPI therapy or tight control of refl ux (as 
determined by ambulatory pH monitoring) leads to lower recur-
rence rates following ablation. Most cohorts reporting follow-up 
aft er ablation, however, have continued patients on twice-a-day PPI 
therapy. Treatment of refl ux following successful ablation should 
follow the same principles as outlined in the section on endoscopic 
therapy of BE. Th e goal of medical treatment should be the control 
of symptoms of refl ux and the prevention or healing of esophagitis.
 ENDOSCOPIC ERADICATION THERAPY: TRAINING 
AND EDUCATION
 Recommendation 
 45 .  Endoscopists who plan to practice endoscopic ablative pro-
cedures should additionally off er EMR (strong recommenda-
tion, very low level of evidence). 
 40 .  Endoscopic surveillance following CEIM, for patients with 
HGD or intramucosal carcinoma before ablation, is recom-
mended every 3 months for the fi rst year following CEIM, 
every 6 months in the second year, and annually thereaft er 
(conditional recommendation, low level of evidence). 
 41 .  In patients with LGD before ablation, endoscopic surveil-
lance is recommended every 6 months in the fi rst year 
following CEIM, and annually thereaft er (conditional 
recommendation, low level of evidence). 
 42 .  During endoscopic surveillance aft er CEIM, careful inspec-
tion of the tubular esophagus and GEJ (in antegrade and 
retrograde views) should be performed with high-resolution 
white light imaging and narrow band imaging to detect 
mucosal abnormalities that may refl ect recurrent IM 
and/or dysplasia (strong recommendation, low level of 
evidence). 
 43 .  Treatment of recurrent metaplasia and/or dysplasia should 
follow guidelines for the treatment of metaplasia/dysplasia 
in BE before ablation (strong recommendation, low level of 
evidence). 
 44 .  Following CEIM, the goal of medical antirefl ux therapy 
should be control of refl ux as determined by absence of 
frequent refl ux symptoms (more than once a week) and/or 
esophagitis on endoscopic examination (conditional recom-
mendation, very low level of evidence). 
 Summary of evidence
 Following CEIM, the recurrence rate for IM is not inconsider-
able, with some cohorts demonstrating rates of ≥20% at 2–3 years 
following CEIM ( 164,173,174 ). Th ough most recurrences are 
nondysplastic, up to a quarter may be dysplastic, including EAC 
( 164,175 ). Variability in reported recurrence rates may be partially 
explained by diff erences in defi nitions of recurrence among stud-
ies: with some studies reporting recurrences located only in the 
tubular esophagus ( 176 ), whereas others reporting recurrent IM in 
both the esophagus and the GEJ/cardia ( 177 ). Th e signifi cance of 
recurrent IM without dysplasia at the GEJ aft er CEIM is currently 
unclear. Cohorts treated with either combination therapy (EMR 
followed by ablation) ( 178 ) or single modality therapy (EMR alone) 
( 173 ) have reported comparable recurrence rates. Recurrence rates 
also appear to be similar across diff erent ablation modalities, with 
similar rates being described following cryotherapy ( 168 ) and pho-
todynamic therapy for the treatment of dysplastic BE ( 179 ).
 Careful endoscopic surveillance with biopsies is hence recom-
mended following CEIM to detect recurrent IM. Careful inspec-
tion of both tubular esophagus (in the region of the prior BE 
segment) and the GEJ (on antegrade and retrofl exed views) is 
important. Both the interval of these examinations and the biopsy 
protocol are currently based on expert opinion and on intervals 
reported in published cohort studies ( 176,180 ). Endoscopic sur-
veillance for patients with baseline HGD every 3 months in the 
fi rst year following CEIM, every 6 months in the second year, and 
annually thereaft er is currently recommended. For patients with 
baseline LGD, endoscopic surveillance is recommended every 6 
months in the fi rst year following CEIM, and annually thereaf-
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 Summary of evidence
 Th ere are currently little if any data to determine the exact thresh-
olds for training and education for the performance of endoscopic 
ablative therapy of BE. Common sense and expert opinion suggest 
that a number of core competencies are warranted before embark-
ing on endoscopic ablative therapy, the application of which is 
only one component in the management of these patients ( 191 ). 
Adequate training and expertise in the recognition of mucosal 
lesions that may harbor neoplasia is critical in order to target such 
endoscopic abnormalities with EMR. It is well known that EMR 
of mucosal abnormalities alters the pathologic stage in ∼ 50% of 
patients with clear management implications ( 113,192 ). Further-
more, all randomized clinical trials of radiofrequency ablation 
required endoscopic resection of mucosal abnormalities before 
application of radiofrequency ablation. Follow-up aft er applica-
tion of radiofrequency ablation also demonstrates the develop-
ment of nodular lesions in a subset of patients, warranting EMR. 
Finally, expertise in recognition and management of potential 
complications of endoscopic therapy, most notably bleeding, 
strictures, and perforation, are warranted. As such, it makes little 
sense to off er or train in radiofrequency ablation for fl at BE in the 
absence of training in EMR.
 To date, there is little information on the learning curve to 
acquire these skills. Th e recent British Society of Gastroentero-
logy guideline statement recommends, based on expert opinion, 
a minimum of 30 supervised endoscopic resections and 30 abla-
tions for competence ( 10 ). For radiofrequency ablation, a single 
endoscopist case series demonstrated no diff erence in eradication 
of IM, complications, and procedure time in the initial 25% vs. 
later 75% of cases and the initial 50% vs. later 50% of cases ( 193 ). 
On the other hand, work from a multicenter tertiary center con-
sortium found variable CEIM rates ranging from 62 to 88% among 
seven diff erent endoscopists with a positive correlation between 
both patient volume and radiofrequency ablation volume and the 
rate of complete remission of IM ( 194 ). However, there was no 
threshold volume for success. For EMR, a multicenter Dutch study 
that examined a structured training program for EMR found no 
diff erence in complication rates, completeness of resection, and 
time per resection for the fi rst 10 vs. second 10 resections ( 195 ). Of 
note, only 29% of resections in this study involved the multiband 
ligator approach, whereas the remainder were performed with the 
cap technique.
 CONCLUSION
 Care of the patient with BE has evolved rapidly in the past decade. 
Th e above analysis attempts to encapsulate these advances and 
to present, in a concise manner, “best practices” for the care of 
these patients. Th ese recommendations should not be construed 
as practice standards or quality measures—as always, clinical cir-
cumstances should dictate the best care for each patient.
 Th ese guidelines diff er markedly from their predecessor in sev-
eral areas. Th ese include the expanded use of endoscopic ablative 
therapy, especially their extension to patients with LGD, based on 
high-quality level 1 evidence demonstrating diminished risk of 
progression and/or adenocarcinoma aft er treatment. In addition, 
there is further refi nement of screening recommendations, based 
on data demonstrating both a lower risk of EAC in patients with 
nondysplastic BE and a better understanding of the impact of gen-
der and anthropomorphics on risk. Th e most important of these 
changes is the recommendation that females with GERD symp-
toms no longer undergo routine screening. Finally, surveillance 
recommendations have been attenuated to recognize the relatively 
rare occurrence of progression in nondysplastic BE, as well as the 
unclear nature of benefi t inherent in endoscopic surveillance.
 It is likely that the development of several technologies will 
cause further evolution in care of patients with BE. Several areas 
in particular appear poised for paradigm-shift ing advances. Th ese 
include the evolution of biomarkers to predict risk in BE, the use 
of advanced imaging and biomolecular technologies to allow 
recognition of areas of neoplasia within BE, and the advent of 
less invasive and less expensive modalities for screening patients 
for BE. All of these areas off er the promise of improved care at 
reduced costs. Although the time horizon of these developments 
is unpredictable, it is likely that advances in one or more of these 
areas will cause marked changes in the next iteration of these 
guidelines.
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